Xellia Pharmaceuticals ApS

Xellia Pharmaceuticals ApS

 

 

 

Xellia Pharmaceuticals is the leading supplier of important anti-infectives Vancomycin and Colistimethate Sodium (CMS) built on more than 100 years’ pharmaceutical industry experience. Headquartered in Copenhagen, Denmark and owned by Novo A/S, Xellia Pharmaceuticals has more than 1200 employees globally.

From manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticals excels within innovative product development to deliver high quality products to its customers.

China is a very important part of Xellia’s global strategy. In China, Xellia’s sales office is located in Shanghai and production site in Taizhou. Xellia’s production establishment in China is based on a joint-venture with Hisun Pharmaceuticals. At the Taizhou site Xellia is producing critical life-saving anti-infectives Vancomycin, Bacitracin and Bacitracin Zinc. With advanced technology from Xellia and an cGMP record, the products produced at the Taizhou site are sold to internationally recognized pharmaceutical companies

 

雅赛利制药是一家生产重要抗感染药物如万古霉素和多粘菌素的领先制药企业,有着百余年丰富的药物生产经验。总部设立在丹麦哥本哈根,隶属于Novo集团,雅赛利制药在全球拥有超过1200位员工。

 从拥有先进装备的美国、中国、丹麦和匈牙利工厂,到挪威和克罗地亚的研发中心,雅赛利制药始终致力于为顾客提供高质量的创新型产品。

 中国是雅赛利非常重要的全球战略部署之一。在中国,雅赛利的销售办公室位于上海,制造工厂位于台州。这家制造工厂是与海正药业合作的合资企业。台州工厂的产品是挽救生命的抗感染药物万古霉素、杆菌肽和杆菌肽锌。源于雅赛利制药的先进技术和卓越的GMP管理,台州工厂的产品远销世界各地知名的制药企业。

Website: http://www.xellia.com